Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057


News SummaryMost relevantAll newsSector newsTweets 

Shire PLC : Shire Buys 50,953 Own Shares to Hold in Treasury

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 09:57am CET

LONDON--Biopharmaceutical company Shire PLC (SHP.LN), said Friday it purchased 50,953 of its ordinary shares of 5 pence each on February 21, through both direct purchases of Ordinary Shares and through the purchase of Ordinary Shares underlying ADRs.


-The purchased shares will be held as treasury shares

-The highest and lowest price paid for the directly acquired Ordinary Shares was 2083.00 pence per share and 2047.00 pence per share respectively and for those Ordinary Shares acquired through the purchase of ADRs was 3148.50 cents per share and 3139.33 cents per share respectively.

-Shire shares at 0840 GMT traded up 5.0 pence, or 0.2%, at GBP20.77, valuing the company at GBP11.55 billion.

-Write to Razak Musah Baba at razak.baba@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE PLC
02/28 SHIRE : argenx announces extension of therapeutic antibody alliance with Shire
02/24DJSHIRE : Files 8K - Other Events
02/24 SHIRE PLC : Other Events, Financial Statements and Exhibits (form 8-K)
02/24 DIRECTOR DEALINGS SUMMARY : Shire Non-Executive Stroucken Ups Stake
02/24 SHIRE : New England Journal of Medicine Publishes Phase 1b Results for Shire's I..
02/24 SHIRE : Elections for the interim dividend ...
02/24 SHIRE : Elections for the interim dividend
02/24 SHIRE : Gets Positive Opinion From EMA Committee For Natpar
02/24 SHIRE : CHMP Recommends EU Conditional ...
02/24 DIRECTOR DEALINGS : Shire Non-Executive Director Buys 14,000 ADRs
More news
Sector news : Pharmaceuticals - NEC
07:15p Banks, builders boost European shares as Trump-trade back on
04:21p EpiPen maker Mylan forecasts strong 2017; shares jump
12:41p Bayer sells 11 percent of Covestro for 1.46 billion euros
11:18a Banks, basic resources lift European shares on Trump-trade
09:44aDJCovestro Shares Nosedive After Bayer Reduces Stake
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/28 Cowen's Cacciatore doesn't see upside in Endo, cuts price target to $16; shar..
02/27 Tracking Stephen Mandel's Lone Pine Capital Portfolio - Q4 2016 Update
02/24 The Risks Keep Rising For Roche's Hemophilia Hope
02/24 European advisory committee backs conditional approval of Shire's Natpar for ..
02/23 Early-stage study shows encouraging results for Shire's candidate for heredit..
Financials ($)
Sales 2017 15 254 M
EBIT 2017 5 884 M
Net income 2017 3 028 M
Debt 2017 18 111 M
Yield 2017 0,61%
P/E ratio 2017 16,82
P/E ratio 2018 12,91
EV / Sales 2017 4,77x
EV / Sales 2018 4,16x
Capitalization 54 639 M
More Financials
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 74,0 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
David R. Ginsburg Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC3.63%54 954
JOHNSON & JOHNSON6.24%332 993
ROCHE HOLDING LTD.4.73%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG5.06%203 039
MERCK & CO., INC.12.38%181 558
More Results